Health-related quality of life (HrQoL) of first-line treatments in metastatic renal cell carcinoma (mRCC): A network meta-analysis.
Oluseyi Abidoye(Mayo Clinic), Irbaz Bin Riaz(Mayo Clinic), Ammad Raina(Clinica Sierra Vista), Kaneez Zahra Rubab Khakwani(University of Arizona), Kunwer Sufyan Faisal(Ziauddin University), Manal Imran(Dow University of Health Sciences), Syed Arsalan Ahmed Naqvi(Mayo Clinic Hospital), Brian A. Costello(Mayo Clinic in Arizona), Parminder Singh(WinnMed), Nikita Tripathi(University of Phoenix), Haidar Abdul‐Muhsin(Mayo Clinic in Arizona), Alan H. Bryce(Mayo Clinic Hospital)
Cited by 0
Related Papers
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration
|Journal of Clinical Oncology|2020|676
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592